IN2015KN00571A - - Google Patents
Info
- Publication number
- IN2015KN00571A IN2015KN00571A IN571KON2015A IN2015KN00571A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A IN 571KON2015 A IN571KON2015 A IN 571KON2015A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A
- Authority
- IN
- India
- Prior art keywords
- vascular
- present disclosure
- ntprocnp
- finding
- subject
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682729P | 2012-08-13 | 2012-08-13 | |
| PCT/NZ2013/000142 WO2014027899A1 (en) | 2012-08-13 | 2013-08-13 | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015KN00571A true IN2015KN00571A (https=) | 2015-07-17 |
Family
ID=50101335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN571KON2015 IN2015KN00571A (https=) | 2012-08-13 | 2013-08-13 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10012656B2 (https=) |
| EP (1) | EP2883060B1 (https=) |
| JP (1) | JP6423788B2 (https=) |
| CN (1) | CN104937420B (https=) |
| AU (1) | AU2013303302B2 (https=) |
| CA (1) | CA2882116A1 (https=) |
| IN (1) | IN2015KN00571A (https=) |
| SG (2) | SG11201501145SA (https=) |
| WO (1) | WO2014027899A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| IN2015KN00571A (https=) * | 2012-08-13 | 2015-07-17 | Otago Innovation Ltd | |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| US20160106821A1 (en) * | 2014-10-20 | 2016-04-21 | Massachusetts Institute Of Technology | Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers |
| US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| EP3400021A1 (en) * | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
| TWI776812B (zh) * | 2016-06-02 | 2022-09-11 | 荷蘭商菲林公司 | 血管收縮素-1-受體拮抗劑 |
| WO2018216580A1 (ja) * | 2017-05-22 | 2018-11-29 | 東ソー株式会社 | アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬 |
| WO2019199869A1 (en) * | 2018-04-10 | 2019-10-17 | Quanterix Corporation | Quantification of biomarkers present in physiological samples |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT407580B (de) * | 1999-08-20 | 2001-04-25 | Biomedica Gmbh | Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay |
| WO2004099139A1 (en) | 2000-09-15 | 2004-11-18 | Baylor University | Indole-containing compounds with anti-tubulin and vascular targeting activity |
| DE602004030342D1 (de) * | 2003-06-17 | 2011-01-13 | Otago Innovation Ltd | Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden |
| DE10338733A1 (de) | 2003-08-22 | 2005-03-24 | Berdel, Wolfgang E., Prof. Dr.med. | Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie |
| US20100041989A1 (en) | 2006-09-29 | 2010-02-18 | The Trustees Of The University Of Pennsylvania | Use of ultrasound as an antivascular agent |
| EP2583106A1 (en) * | 2010-06-18 | 2013-04-24 | Cézanne S.A.S. | Markers for the prognosis and risk assessment of pregnancy-induced hypertension and preeclampsia |
| WO2013095759A1 (en) * | 2011-12-23 | 2013-06-27 | Mayo Foundation For Medical Education And Research | Assessing renal structural alterations and outcomes |
| IN2015KN00571A (https=) * | 2012-08-13 | 2015-07-17 | Otago Innovation Ltd |
-
2013
- 2013-08-13 IN IN571KON2015 patent/IN2015KN00571A/en unknown
- 2013-08-13 CA CA2882116A patent/CA2882116A1/en not_active Abandoned
- 2013-08-13 SG SG11201501145SA patent/SG11201501145SA/en unknown
- 2013-08-13 US US14/421,423 patent/US10012656B2/en not_active Expired - Fee Related
- 2013-08-13 EP EP13829360.0A patent/EP2883060B1/en not_active Not-in-force
- 2013-08-13 SG SG10201700872TA patent/SG10201700872TA/en unknown
- 2013-08-13 JP JP2015527420A patent/JP6423788B2/ja not_active Expired - Fee Related
- 2013-08-13 CN CN201380053106.1A patent/CN104937420B/zh not_active Expired - Fee Related
- 2013-08-13 AU AU2013303302A patent/AU2013303302B2/en not_active Ceased
- 2013-08-13 WO PCT/NZ2013/000142 patent/WO2014027899A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014027899A1 (en) | 2014-02-20 |
| AU2013303302A1 (en) | 2015-03-12 |
| CA2882116A1 (en) | 2014-02-20 |
| SG10201700872TA (en) | 2017-04-27 |
| US20150241451A1 (en) | 2015-08-27 |
| AU2013303302B2 (en) | 2017-10-12 |
| EP2883060A4 (en) | 2016-06-29 |
| JP6423788B2 (ja) | 2018-11-14 |
| EP2883060A1 (en) | 2015-06-17 |
| CN104937420B (zh) | 2018-07-03 |
| JP2015526725A (ja) | 2015-09-10 |
| CN104937420A (zh) | 2015-09-23 |
| EP2883060B1 (en) | 2018-03-21 |
| US10012656B2 (en) | 2018-07-03 |
| SG11201501145SA (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015KN00571A (https=) | ||
| PH12018500513A1 (en) | Methods for diagnosing and evaluating non-alcoholic steatohepatitis | |
| MX2016013635A (es) | Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes. | |
| MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
| HK1218576A1 (zh) | 结核病生物标志物及其用途 | |
| EA201591582A1 (ru) | Анализ транскриптома материнской плазмы с применением массивного параллельного секвенирования рнк | |
| MX2020011415A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| WO2017031067A3 (en) | Biomarkers for treatment of alopecia areata | |
| BR112015030293A2 (pt) | compensação de dados magnéticos para inspeções de mapeamento de veículo submarino autônomo | |
| BR112015009948A2 (pt) | antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios | |
| BR112015017767A2 (pt) | sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo | |
| WO2014140926A3 (en) | Systems, methods, and computer-readable media for identifying when a subject is likely to be affected by a medical condition | |
| WO2011047033A3 (en) | Biomarker for identification of melanoma tumor cells | |
| WO2013023048A3 (en) | Synergistic interaction of weak cation exchange resin and magnesium oxide | |
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| MX2024001909A (es) | Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores. | |
| WO2014169226A3 (en) | Methods of diagnosing and treating chronic pain | |
| BR112017009976A2 (pt) | gado de leite híbrido e sistemas para maximizar vantagem híbrida | |
| BR112017011642A2 (pt) | composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+. | |
| EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| FR2979346B1 (fr) | Nanocorps anti-vcam-1 | |
| WO2015085055A3 (en) | Methods of treating or preventing pruritis by blocking natriuretic polypeptide b | |
| WO2014100602A8 (en) | Treatment of egf-receptor dependent pathologies |